Research-Driven Treatments Target Improved Outcomes

At University Hospitals Seidman Cancer Center, our oncology specialists conduct leading-edge clinical research focused on developing the most effective ways of managing breast cancer—from reducing incidence in high-risk patients to controlling disease that has spread throughout the body. To do so, we invest a significant amount of time and resources in testing new, innovative treatments that may be transferred into practice.

Our rich history of advancements in breast cancer care includes the following:

  • We have pioneered the use of cord blood transplants.
  • We were at the forefront of research toward a breast cancer vaccine.
  • Our physician-researchers are published in national and international medical journals and have tested more than half of the new cancer drugs that have made a major impact in survival rates.
  • We participate in national advisory boards and lend our expertise to lawmakers and policymakers.
  • Our physicians are successful innovators and hold many medical patents for their pioneering work.

Clinical Trials Form Foundation for Successful Treatment

Clinical trials are research studies used to evaluate the effectiveness of new strategies to treat breast cancer. Results of such research often translate into new, powerful therapies and may benefit the patients involved, as well as other patients being treated around the world. With over 300 ongoing clinical trials, patient participation at UH Seidman Cancer Center is five times the national average.

UH Seidman Cancer Center researchers have successfully conducted numerous clinical trials, including:

  • Preoperative chemotherapy for newly diagnosed breast cancer; this technique can improve surgical outcomes and offer more opportunities to conserve breast tissue
  • Studies on many of the medications used to treat breast cancer that have made a major impact in survival rates, including but not limited to Herceptin (trastuzumab), Navelbine (vinorelbine), Abraxane (paclitaxel), Arimidex (anastrozole), Gemzar (gemcitabine), Zometa (zoledronic acid), Ixempra (ixabepilone) and Taxotere (docetaxel)
  • The use of radiation concurrent with chemotherapy
  • Studies of the effectiveness of partial breast irradiation and interoperative radiation
  • Cardiac-sparing radiation techniques
  • Breast cancer prevention for high-risk patients